To determine whether the antitumour effects of these compounds result from targeting MET signalling specifically, we tested the growth inhibition efficacies of these compounds in four human cancer cell lines neuroblastoma SK-N-SH, colorectal cancer DLD1, triple-negative breast cancer MDA-MB-231 and lung cancer A549 without MET gene amplification or overexpression (Figure 3) [35]. The gene discussed is MET; the disease is neuroblastoma.